KRDO1mon
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes ... but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.
Business Wire23d
PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
SURPASS-ET Clinical Results Clinical Trial Overview SURPASS-ET (NCT04285086 ... compared to a reduction from 39.7% to 37.3% (-2.4% change) in the Anagrelide group. These results suggest that ...